NCT04197713: Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations, ATM, BRCA+
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 1
Drug Category: Misc Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have received at least one line of systemic therapy in the advanced/metastatic setting
Exclusions: Patients who have not had prior treatment with PARP inhibitors

Comments are closed.

Up ↑